Cantor Fitzgerald reiterates overweight rating on Roivant Sciences stock

Cantor Fitzgerald reiterated its overweight rating on Roivant Sciences (ROIV) following an investor call on brepocitinib, an oral TYK2/JAK1 inhibitor, with Phase 3 results in Dermatomyositis expected in the second half of 2025 and a potential launch in early 2027; analysts are bullish with price targets ranging from $12 to $22. Roivant is also advancing brepocitinib in Non-infectious uveitis and plans to release proof-of-concept data in cutaneous sarcoidosis, while Pulmovant, a subsidiary, announced positive Phase 1 data for mosliciguat, an inhaled treatment for pulmonary hypertension.

Analysis

Roivant Sciences (ROIV), a $7.55 billion market cap biotech, benefits from continued analyst confidence, with Cantor Fitzgerald maintaining an overweight rating following an investor call focused on its oral TYK2/JAK1 inhibitor, brepocitinib, for Dermatomyositis (DM). Key upcoming catalysts include Phase 3 trial results for brepocitinib in DM, expected in the second half of 2025, with a potential launch targeted for early 2027 if successful. This optimism is shared across the analyst community, evidenced by price targets ranging from $12 to $22, and reiterated Buy ratings from H.C. Wainwright ($18.00 price target) and Guggenheim ($15.00 price target). Financially, InvestingPro data indicates Roivant possesses a strong balance sheet with more cash than debt, although current metrics suggest the stock may be trading above its Fair Value. The company is actively expanding brepocitinib's potential, with a Phase 3 trial in Non-infectious uveitis (NIU) expecting results in H1 2027 and proof-of-concept data for cutaneous sarcoidosis anticipated in H2 2026. Cantor Fitzgerald highlighted that while the primary risk for the brepocitinib DM trial is the placebo response on the Total Improvement Score (TIS), new pooled data on steroid tapering and baseline characteristics could mitigate this concern. Further positive momentum comes from Roivant's subsidiary, Pulmovant, which announced well-tolerated and effective Phase 1 data for mosliciguat, an inhaled treatment for pulmonary hypertension. Strategic developments also include Eric Venker's appointment as CEO of Immunovant (IMVT), aligning with Roivant's broader pipeline and therapeutic area expansion goals.

Key Decisions for Investors

• Investors should weigh Roivant's significant pipeline catalysts, particularly the H2 2025 brepocitinib Phase 3 data in Dermatomyositis and strong analyst support, against its current valuation which InvestingPro suggests may be above Fair Value when considering new or existing positions.
• Close monitoring of the brepocitinib Phase 3 trial results for Dermatomyositis is critical, with specific attention to the placebo response rates on the Total Improvement Score, as this represents a key identified risk.
• The ongoing development of brepocitinib in additional indications like Non-infectious uveitis and cutaneous sarcoidosis, positive early data for mosliciguat, and strategic initiatives at Immunovant offer potential diversification and long-term value drivers that warrant careful observation.